Showing results (91-100 of 604) with videos related to

Sort By:
Pageof 61
Pharmacoeconomics - Open|February 15, 2018
Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in SwedenUgne Sabale, Mattias Ekman, Daniel Thunström, et al.
Pharmacoeconomics - Open|February 16, 2018
Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery DiseaseJames Lomas, Miqdad Asaria, Laura Bojke, et al.
Pharmacoeconomics - Open|May 2, 2018
Accommodation and Health Costs of Deinstitutionalized People with Mental Illness Living in Residential Services in BrazilDenise Razzouk
Pharmacoeconomics - Open|May 24, 2018
Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in EnglandD Lee, A Amadi, J Sabater, et al.
Pharmacoeconomics - Open|August 9, 2018
Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone PalmitateBruno Emond, Kruti Joshi, Antoine C El Khoury, et al.
Pharmacoeconomics - Open|April 7, 2018
Resources and Costs Associated with the Treatment of Advanced and Metastatic Gastric Cancer in the Mexican Public Sector: A Patient Chart ReviewMiguel Quintana, José A Toriz, Diego Novick, et al.
Pharmacoeconomics - Open|April 7, 2018
Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders' Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)Martina Garau, Grace Hampson, Nancy Devlin, et al.
Pharmacoeconomics - Open|April 7, 2018
Cost Effectiveness of Stapled Haemorrhoidopexy and Traditional Excisional Surgery for the Treatment of Haemorrhoidal DiseaseMary M Kilonzo, Steven R Brown, Hanne Bruhn, et al.
Pharmacoeconomics - Open|April 7, 2018
Using Cerebrospinal Fluid Biomarker Testing to Target Treatment to Patients with Mild Cognitive Impairment: A Cost-Effectiveness AnalysisTzeyu L Michaud, Robert L Kane, J Riley McCarten, et al.
Pharmacoeconomics - Open|April 7, 2018
Impact of Fluid Choice in Systemic Inflammatory Response Syndrome Patients on Hospital Cost SavingsSuzanne Laplante, Dilip U Makhija, Sibyl H Munson, et al.
Pageof 61